Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
VK2809
PPT - Promising Results of VK2809 in NAFLD: Phase 2 Study PowerPoint ...
VK2809 (MB-07811) | THRβ agonist | Probechem Biochemicals
VK2809 in NAFLD - Slideset Download - Vienna 2019 | CCO
VK2809 - Viking Therapeutics
Rohit Loomba results from the 52 Week Phase 2b VOYAGE Trial of VK2809 ...
FreeBioAlpha on LinkedIn: VK2809 An oral THR agonist prodrug with ...
VKTX: IND Filed for VK0214 in X-ALD; New Data for VK2809 to be ...
Vk2809 - YouTube
New Fatty Liver Clinical Trial: VK2809 for Fatty Liver - YouTube
Results From the 52-Week Phase 2b VOYAGE Trial of VK2809 in Patients ...
Análisis VK2809
VKTX: VK2809 IND Filed; P2b Trial to Initiate in 4Q19…
VK2809 treatment reduces NASH-related liver fat, fibrosis: Phase 2b trial
Viking Therapeutics Nears Obesity Drug Breakthrough with Phase 3 VK2735 ...
VKTX launches $500M shelf after full enrollment of phase 3 obesity drug ...
Biotech Sector Consolidation: How Novo Nordisk's Akero Acquisition ...
Which biotech companies are developing next-gen GLP-1 alternatives—and
| A structure-based representation of TRβ-selective thyromimetics. (A ...
Ligand Pharmaceuticals Terminates TRβ Deal with Viking Therapeutics ...
Thyroid hormone receptor-beta agonist achieves ‘robust reduction’ in ...
(PDF) Regulation of gene transcription by thyroid hormone receptor β ...
Chemical structure, THR-β activity, and PK properties of CS27109: (a ...
aleniglipron
VKTX vs LLY in Obesity: Underdog vs Titan — A Real Pipeline & Data ...
Viking Therapeutics Presents New Data from Phase 2b VOYAGE Study of ...
Ligand Terminates TR-Beta License with Viking
Future Tech investment articles generated using Ai technology : "NASH ...
Ligand moves to terminate Viking’s TRβ program amid dispute
DRUCK LEICESTER PTX EX-0129A PRESSURE TRANSMITTER PTX
Terns, trailing rivals, hits in phase 2 NASH trial but fails to quash ...
Viking (VKTX) — VKTX Delivers Excellent Phase IIb VOYAGER Data in NASH
Solid CPI Bumps Biotech Index Up 1.47%. Can the Risk-On Mentality Move ...
Viking Therapeutics' Stock Plunge: A Closer Look
MAIDEN The MAFLD Consortium on LinkedIn: MAFLD Pandemic: Updates in ...
Viking Therapeutics, Inc. (VKTX) Nears Obesity Drug Breakthrough with ...
Monaco on Twitter: "RT @JamesEKrause: $VKTX VOYAGE Ph2b positive NASH ...
Chasing Madrigal, Viking sails higher after NASH therapy slays midphase ...
Jim Cramer does his homework on Viking Therapeutics
MB-07811 (VK2809) | CAS 852948-13-1 | AbMole BioScience | MB-07811 Price
JP Morgan Lowers Price Target for Viking Therapeutics (VKTX) to
Bernie Gold (@BernardGoldste6) / Posts / X
This might be the niche peptide stock for 2026... The fundamentals are ...
Is Viking Therapeutics Poised to Disrupt the Weight-Loss Market
Viking Therapeutics (@Viking_VKTX) / Posts / X
9 MASH Meds - LiverRight: Virtual Liver Disease Clinic
Gannex posts midphase data on NASH asset at center of trade secret row ...
Frontiers | Discovery of a novel, liver-targeted thyroid hormone ...
Viking Therapeutics's NASH drug succeeds in a mid-stage trial ...
Viking Therapeutics Could Be Pharma’s Next Big Buyout Target
Down 65%, Is Viking Therapeutics Stock a Buy on the Dip?
Viking Therapeutics Clears Mid-Stage NASH Trial - Biomarker News
Structure Therapeutics vs. Viking Therapeutics: Which Weight-Loss Drug ...
I might have just found a niche peptide stock. $VKTX is the name. Here ...
Viking Therapeutics Could Be Pharma's Next Big Buyout Target - Briefly
VKTX Stock Performance New Zealand | 2026 NZ Finance Guide
Viking Therapeutics' Stock Plunge: A Blip or a Long-Term Concern?
Viking Therapeutics Announces Plans for Public Offering of Common Stock ...
Prospective NASH market flips from failure to overcrowded
Viking Therapeutics' VK2735 shows unmatched efficacy in obesity trial ...
2 'Strong Buy' Biotech Stocks With 120% or More Upside Potential - The ...
Decoding Viking Therapeutics Inc (VKTX): A Strategic SWOT Insigh
Targeting thyroid hormone receptor-β to treat metabolic dysfunction-a ...
Viking Therapeutics to Report Q1 Earnings: What's in the Cards?
Higher Biopharma M&A Activity ‘Almost Inevitable’ in 2025, With Viking ...
Viking Therapeutics to Report Q4 Earnings: Here's What to Know
3 'Strong-Buy'-Rated Russell 2000 Stocks With 54% to 110% Upside - The ...
MarketGauge posted on LinkedIn
Vktx Stock Prediction 2026 - StockPrediction.net
Ligand Pharmaceuticals on LinkedIn: #fda
Viking Therapeutics Reports Third Quarter 2025 Financial Results and ...
THR-β Agonist Market Insights and Market Forecast
肝脏脂肪含量最高降低52%！一款NASH新药IIb期研究成功医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
Is Viking Therapeutics a Buy Now? | The Motley Fool
Transforming Health: Viking Therapeutics’ Innovative Biotech ...
Clinical Trials Revolutionize Patient’s Liver Disease
Nuclear Receptor-Targeted Therapies: Reprogramming Metabolism with TRβ ...
Viking Therapeutics: Strategic Positioning in Metabolic Disease Innovation
Viking Therapeutics: Among the Oversold Biotech Stocks to Buy Now
#molekuleconsulting #decisionvelocity #humint #metabolicsovereignty # ...
Viking Therapeutics (VKTX) Stock Forecast: Analyst Ratings, Predictions ...
Big Movers in Q2... Which Indications are Most Common?
NASH Companies Back in the Spotlight!
HCV-Trials.com : A regularly updated website with all most recent ...
Frontiers | Selective Thyroid Hormone Receptor-Beta (TRβ) Agonists: New ...
VK-2809
MK-0616
Agonisti selettivi del recettore $\beta $ degli ormoni tiroidei nel ...
Future Tech investment articles generated using Ai technology : We ...
VK2809|MB07811——药研档案
解析Madrigal的THR-β选择性激动剂Resmetirom的发现和优化 来源：药渡CyberResmetirom是一款肝脏甲状腺素受体β ...
Regulation of gene transcription by thyroid hormone receptor β agonists ...
Thyroid hormone receptor-β analogues for the treatment of metabolic ...
AZD4144
Viking创新疗法甲状腺受体β亚型激动剂VK2809达主、次要终点，针对脂肪性肝炎
Tides 速递|Viking Therapeutics宣布VK2809在2b期VOYAGE研究取得积极的前期结果医药新闻-ByDrug-一站 ...
第7期 NASH及治疗药物（三） 我司每1-2周就一个药物、疾病、靶点小专题进行专题研究，近期准备把前期研究的内容简化整理一下，做成科普内容 ...
바이킹 테라퓨틱스
선택적 TRβ 작용제 'VK2809', NASH 신약후보로 급부상
Viking Therapeutics Announces Initiation of Phase 2b VOYAGE Study of ...
.jpg){kind=spacer}
.jpg){kind=spacer}
.jpg){kind=spacer}
